Biopolymer-nanoparticle composite implant for tumor cell tracking

Patent metadata

Field	Value
Publication number	US-10799604-B2
Application number	US-201515328711-A
Country	US
Kind code	B2
Filing date	Jul 27, 2015
Priority date	Jul 25, 2014
Publication date	Oct 13, 2020
Grant date	Oct 13, 2020

Abstract

A method of detecting migration of tumor cells is provided by implanting in a region of tumor cells one or more implants having a matrix material of a biocompatible and biodegradable polymer, and a plurality of nanoparticles dispersed within the matrix material and functionalized to bind tumor cells. Nanoparticles bound to the tumor cells that have migrated out of the region can be detected by various imaging modalities. The implant can be in the shape of a brachytherapy spacer or radiotherapy fiducial maker or can be a coating on a brachytherapy spacer or fiducial marker. A method of treating cancer is provided by implanting one or more brachytherapy spacers or fiducial markers including the matrix material and an anti-cancer therapeutic agent dispersed within the matrix material.

First claim

What is claimed is:

1. A method of detecting migration of tumor cells out of a region of tumor cells, the method comprising:
(a) implanting one or more implants in a region of tumor cells in a patient in need thereof, the implant comprising:
a matrix material comprising a biocompatible and biodegradable polymer, and
a plurality of nanoparticles functionalized to bind and track said tumor cells, the functionalized nanoparticles dispersed within the matrix material, conjugated to a tumor-targeting moiety, and conjugated to a detection moiety;

(b) waiting until nanoparticles are released from the implant, the released nanoparticles bind to tumor cells in said region, and nanoparticle-bound tumor cells migrate out of said region; and
(c) detecting the nanoparticle-bound tumor cells after they have migrated out of said region.

2. The method of claim 1 , wherein the detection moiety is selected from the group consisting of a fluorophore, a radiolabel, and a magnetic resonance contrast agent.

3. The method of claim 1 , wherein the tumor-targeting moiety is selected from the group consisting of a tumor-targeting ligand, a peptide, a protein, an aptamer, an oligonucleotide, an antibody, a cell adhesion molecule, a small molecule, and combinations thereof.

4. The method of claim 1 , wherein the detecting step comprises use of photoacoustic imaging, surface enhanced Raman spectroscopy, X-ray computed tomography, magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography, fluorescence imaging, optical coherence tomography, or ultrasound imaging.

5. The method of claim 1 , wherein the implant is a brachytherapy spacer or a radiotherapy fiducial marker.

6. The method of claim 1 , wherein the implant is in form of a gel and the biocompatible and biodegradable polymer is selected from the group consisting of a polyethylene glycol, polyacrylic acid, polyacrylamide, poly(N-isopropylacrylamide), hyaluronic acid, and combinations thereof.

7. The method of claim 1 , wherein the tumor cells are initially present in a primary tumor.

8. The method of claim 1 , wherein the nanoparticles are detected in tumor cells in a blood vessel, in a lymphatic vessel, in a lymphatic node, in a lymphatic organ, or at a metastatic site in a region of the patient to which the tumor cells have migrated.

9. The method of claim 1 , wherein the functionalized nanoparticles comprise a material selected from the group consisting of gold, gadolinium, and iron-oxide.

10. The method of claim 1 , wherein the implant further comprises a therapeutic agent.

11. The method of claim 1 , further comprising detecting a metastasis and treating the metastasis.

12. The method of claim 10 , wherein the therapeutic agent is an anti-cancer agent.

13. The method of claim 10 , wherein the therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, doxorubicin, cisplatin, gemcitabine, a hydrophobic drug, an anti-androgen compound, a small molecule signaling pathway inhibitor, and combinations thereof.

14. The method of claim 13 , wherein the anti-androgen compound is selected from the group consisting of enzaluamide, flutamide, nilutamide, bicalutamide, abiraterone acetate, cyproterone acetate, megestrol acetate, chlormadinone acetate, spironolactone, canrenone, drospirenone, dienogest, norgestimate, ketoconazole, cimetidine, and combinations thereof.

15. The method of claim 13 , wherein the small molecule signaling pathway inhibitor is selected from the group consisting of a PI3K inhibitor, a PARP inhibitor, a PI3K/AKT/mTOR pathway inhibitor, and combinations thereof.

16. The method of claim 10 , wherein the implant has a diameter ranging from 0.5 mm to 1.5 mm, and the therapeutic agent is present in the matrix material at a concentration ranging from 250 to 500 μg/mm length of the implant.

Assignees

• Univ Northeastern
• Brigham & Womens Hospital Inc
• Dana Farber Cancer Inst Inc

Inventors

• Kumar Rajiv
• Sridhar Srinivas
• Ngwa Wilfred
• Cormack Robert
• Makrigiorgos Gerassimos

Classifications

• A61L2300/256

  Antibodies, e.g. immunoglobulins, vaccines · CPC title

• A61L2400/12

  Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61B2090/3966

  Radiopaque markers visible in an X-ray image · CPC title